Two Sigma Advisers
INM icon

Two Sigma Advisers’s InMed Pharmaceuticals INM Stock Holding History

Two Sigma Advisers’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-97
Closed -$23K – 2642
2022
Q2 		$23K Sell
97
-212
-69% -$81.1K ﹤0.01% 2541
2022
Q1 		$146K Sell
309
-103
-25% -$54.1K ﹤0.01% 2438
2021
Q4 		$270K Buy
+412
New +$319K ﹤0.01% 2173

Other funds holding INM

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Two Sigma Advisers's INM Position: Q3 2022 in Review

Two Sigma Advisers sold out of InMed Pharmaceuticals (INM) in Q3 2022, closing a stake of 97 shares — an estimated $23K sold.

Two Sigma Advisers first reported a position in INM in Q4 2021 and held it in 3 quarters. The position peaked at $270K in Q4 2021. 11 funds tracked by Wall St. Rank hold INM as of Q3 2022.

  • Two Sigma Advisers reported no remaining InMed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 97 InMed Pharmaceuticals shares in Q3 2022, an estimated $23K.
  • Two Sigma Advisers first reported a position in InMed Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Two Sigma Advisers's InMed Pharmaceuticals position peaked at $270K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.